威高骨科-2024 年收益符合预期；2025 年两位数增长目标，中期呼吁谨慎执行

更多资料加入知识星球：水木调研纪要 关注公众号：水木Alpha March 26, 2025 10:35 AM GMT Shandong Weigao | Asia Pacific M Update 2024 Earnings In Line; Double- digit % Growth Target for 2025, and Mid-term Calls for Prudent Execution Reaction to earnings In-line Financial results versus consensus Modest revision higher Direction of next 12-month consensus EPS Shandong Weigao (1066.HK, 1066 HK) China Healthcare | China Source: Company data, Morgan Stanley Research Key Takeaways 2024 segment performance: Sales of general consumables fell ...